ES8801643A1 - Un metodo para producir nuevos derivados del acido ascorbico - Google Patents

Un metodo para producir nuevos derivados del acido ascorbico

Info

Publication number
ES8801643A1
ES8801643A1 ES555014A ES555014A ES8801643A1 ES 8801643 A1 ES8801643 A1 ES 8801643A1 ES 555014 A ES555014 A ES 555014A ES 555014 A ES555014 A ES 555014A ES 8801643 A1 ES8801643 A1 ES 8801643A1
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
ascorbic acid
compositions containing
acid derivatives
containing ascorbic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES555014A
Other languages
English (en)
Other versions
ES555014A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP1985/000272 external-priority patent/WO1986006720A1/ja
Priority claimed from PCT/JP1985/000340 external-priority patent/WO1986007592A1/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES555014A0 publication Critical patent/ES555014A0/es
Publication of ES8801643A1 publication Critical patent/ES8801643A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

METODO PARA LA PRODUCCION DE DERIVADOS DE ACIDO ASCORBICO, DE FORMULA GENERAL (I). COMPRENDE LAS OPERACIONES DE SOMETER UN DERIVADO DEL ACIDO ASCORBICO, DE FORMULA GENERAL (II), EN LA QUE R1 ES UN RESTO ORGANICO QUE TIENE UN PESO MOLECULAR COMPRENDIDO ENTRE 15 Y 700; Y R2 ES HIDROGENO O HIDROXILO, A UN PROCESO DE ACILACION O FOSFORILACION EN UN DISOLVENTE ORGANICO Y EN PRESENCIA DE UNA BASE COMO CATALIZADOR, REALIZANDOSE DICHA OPERACION A UNA TEMPERATURA COMPRENDIDA ENTRE C100 Y 50 GRADOS Y DURANTE UN PERIODO DE TIEMPO COMPRENDIDO ENTRE 1 Y 10 HORAS; Y DE, EN CASO DE QUE SE LLEVE A CABO UNA ACILACION, REALIZAR, CUANDO SEA NECESARIO, UNA MIGRACION DEL ACILO O DESACILACION. DE APLICACION COMO AGENTES PARA LA PROFILAXIS Y MEJORIA DE LOS TRASTORNOS FUNCIONALES CIRCULATORIOS.
ES555014A 1985-05-17 1986-05-16 Un metodo para producir nuevos derivados del acido ascorbico Expired ES8801643A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP1985/000272 WO1986006720A1 (en) 1985-05-17 1985-05-17 Ascorbic acid derivatives, production thereof, and pharmaceutical preparation therefrom
PCT/JP1985/000340 WO1986007592A1 (en) 1985-06-18 1985-06-18 Ascorbic acid derivatives, process for their preparation, and preparations containing same

Publications (2)

Publication Number Publication Date
ES555014A0 ES555014A0 (es) 1988-02-16
ES8801643A1 true ES8801643A1 (es) 1988-02-16

Family

ID=26425982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555014A Expired ES8801643A1 (es) 1985-05-17 1986-05-16 Un metodo para producir nuevos derivados del acido ascorbico

Country Status (17)

Country Link
EP (1) EP0202589B1 (es)
JP (1) JPH0739342B2 (es)
KR (1) KR940000073B1 (es)
CN (1) CN1014409B (es)
AU (1) AU599029B2 (es)
CA (1) CA1293728C (es)
DE (1) DE3669104D1 (es)
ES (1) ES8801643A1 (es)
FI (1) FI862029A (es)
GR (1) GR861228B (es)
HU (1) HU197735B (es)
IE (1) IE59143B1 (es)
IL (1) IL78739A (es)
NO (1) NO172343C (es)
PH (1) PH24833A (es)
PT (1) PT82591B (es)
ZA (1) ZA852614B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2515556B2 (ja) * 1986-08-29 1996-07-10 武田薬品工業株式会社 ヒドロキシブテノライド誘導体およびその製造法
US4826872A (en) * 1986-12-03 1989-05-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treatment of cataract
PH25859A (en) * 1988-01-11 1991-12-02 Takeda Chemical Industries Ltd Composition for treatment of ischemic disorder
JPH0730066B2 (ja) * 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
JPH01228978A (ja) * 1988-03-09 1989-09-12 Nippon Hai Potsukusu:Kk アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤
JP2752080B2 (ja) * 1988-03-09 1998-05-18 株式会社日本ハイポックス アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤
US4939128A (en) * 1988-04-25 1990-07-03 Takeda Chemical Industries, Ltd. Ester of ascorbic acid 2-phosphate and pharmaceutical use
JP2830268B2 (ja) * 1989-01-21 1998-12-02 武田薬品工業株式会社 アスコルビン酸誘導体の製造法
EP0446539A1 (en) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Novel ascorbic acid derivatives
US5270336A (en) * 1990-03-16 1993-12-14 Merrell Dow Pharmaceuticals Inc. Ascorbic acid derivatives
EP0467691A1 (en) * 1990-07-20 1992-01-22 Takeda Chemical Industries, Ltd. Saccharoascorbic acid derivatives and their use
WO1993004055A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Compounds used for the inhibition of hiv-protease
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
AU7636894A (en) * 1993-09-17 1995-04-03 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
JPH07188024A (ja) * 1993-12-27 1995-07-25 Asahi Breweries Ltd 脳循環障害治療剤
FR2715156B1 (fr) * 1994-01-20 1996-03-01 Oreal Mono-esters d'acide cinnamique ou de ses dérivés et de vitamine C, leur procédé de préparation et leur utilisation comme anti-oxydants dans des compositions cosmétiques, pharmaceutiques ou alimentaires.
EP0817786B1 (en) * 1995-03-20 2003-02-19 PHARMACIA & UPJOHN COMPANY Substituted tetronic acids useful for treating hiv and other retroviruses
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
KR100440191B1 (ko) * 2001-08-23 2004-07-12 박관화 항산화 효과 및 높은 안정성을 갖는 아스코르브산 유도체및 그것의 제조방법
KR100440190B1 (ko) * 2001-08-23 2004-07-12 박관화 아카비오신-글루코실 아스코르베이트 및 그의 제조방법
CN1805948A (zh) * 2003-04-21 2006-07-19 塔格拉生物科技有限公司 抗坏血酸的稳定衍生物
FR2946252B1 (fr) * 2009-06-08 2011-07-29 Fabre Pierre Dermo Cosmetique Bis esters d'acide gras insature sur l'acide ascorbique et leurs utilisations cosmetiques
JP6020447B2 (ja) * 2011-05-18 2016-11-02 三菱瓦斯化学株式会社 酸素吸収剤
FR2978963A1 (fr) 2011-08-11 2013-02-15 Ascorbix Nouveaux derives des furanones et composition pharmaceutique les contenant
US20150250169A1 (en) * 2012-09-27 2015-09-10 Nippon Soda Co., Ltd. Ascorbic acid-related compound and plant antiviral agent
US10836844B2 (en) 2015-12-03 2020-11-17 3M Innovative Properties Company Redox polymerizable composition with photolabile reducing agents
US11370940B2 (en) 2017-05-24 2022-06-28 3M Innovative Properties Company Adhesive article and methods of making and using the same
JP6986375B2 (ja) * 2017-06-22 2021-12-22 章博 田井 抗アレルギー剤、メディエーター遊離阻害剤及び内服薬
JP7140325B2 (ja) * 2018-05-23 2022-09-21 株式会社らいむ 化合物、抗アレルギー剤およびメディエーター遊離阻害剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1016834A (en) * 1962-11-26 1966-01-12 Nihon Surfactant Ind Company L Improvements in or relating to 2.6 diesters of ascorbic acid or isoascorbic acid
DE1518988A1 (de) * 1965-05-07 1969-12-11 Herbert Ohg A Verfahren zur Herstellung von Di- und Triestern der Ascorbinsaeure
JPS49833B1 (es) * 1970-09-01 1974-01-10
JPS4867268A (es) * 1971-12-20 1973-09-13
JPS5719109B2 (es) * 1973-07-19 1982-04-20
US4164585A (en) * 1976-07-01 1979-08-14 Cardioquest Corporation Anti-thrombotic compound and method of making and using the same for pharmaceutical purposes
JPS5692260A (en) * 1979-12-26 1981-07-25 Nippon Chemiphar Co Ltd Cyclohexanecarboxylic ester and its preparation
JPS57156479A (en) * 1981-03-24 1982-09-27 Santen Pharmaceut Co Ltd Ascorbic acid derivative
JPS601175A (ja) * 1983-06-16 1985-01-07 Daikin Ind Ltd アスコルビン酸誘導体
JPS6023307A (ja) * 1983-07-15 1985-02-05 Kanebo Ltd 美白化粧料
JPS60130582A (ja) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd 食品用酸化防止剤，アスコルビン酸誘導体およびその製造法
JPS60237083A (ja) * 1984-05-08 1985-11-25 Kao Corp アスコルビン酸エステル

Also Published As

Publication number Publication date
PT82591A (en) 1986-06-01
ES555014A0 (es) 1988-02-16
EP0202589B1 (en) 1990-02-28
IE861313L (en) 1986-11-17
EP0202589A3 (en) 1987-10-07
JPS61263969A (ja) 1986-11-21
HU197735B (en) 1989-05-29
PT82591B (pt) 1988-11-30
IL78739A (en) 1993-01-31
IL78739A0 (en) 1986-08-31
NO861956L (no) 1986-11-18
FI862029A (fi) 1986-11-18
FI862029A0 (fi) 1986-05-14
HUT44249A (en) 1988-02-29
KR940000073B1 (ko) 1994-01-05
GR861228B (en) 1986-09-15
AU599029B2 (en) 1990-07-12
ZA852614B (en) 1986-10-09
NO172343C (no) 1993-07-07
CN1014409B (zh) 1991-10-23
EP0202589A2 (en) 1986-11-26
KR860009001A (ko) 1986-12-19
CA1293728C (en) 1991-12-31
CN86103398A (zh) 1986-12-03
AU5735086A (en) 1986-11-20
DE3669104D1 (de) 1990-04-05
PH24833A (en) 1990-10-30
IE59143B1 (en) 1994-01-12
NO172343B (no) 1993-03-29
JPH0739342B2 (ja) 1995-05-01

Similar Documents

Publication Publication Date Title
ES8801643A1 (es) Un metodo para producir nuevos derivados del acido ascorbico
IL87908A (en) Azaspirane derivatives and immunomodulating pharmaceutical compositions containing same
JPS6440492A (en) Novel pentose
ES547826A0 (es) Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
NZ214787A (en) Arylcyclobutylalkylamines and pharmaceutical compositions
IE40511L (en) Pyridyl piperidine derivatives
ES8707541A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina
FI834702A0 (fi) Nya nitroalifatiska foereningar, deras framstaellningsfoerfarande och anvaendning
GR3007460T3 (es)
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
GB8602116D0 (en) Organic compounds
CA2010982A1 (en) Osteogenesis promotion with use of vitamin d derivatives
IE873301L (en) Anthracycline glycosides
ATE92073T1 (de) Phosphorsaeurediester und salze davon.
ES8203917A1 (es) Un procedimiento para la preparacion de un derivado de nu- cleosido de adenina
ES2092470T3 (es) Derivados de pirrolidina.
NO872982D0 (no) Nye tetracykliske indolderivater.
IE873442L (en) Cephalosporin derivative
ES8602607A1 (es) Un procedimiento para preparar sales de compuestos de fenantreno-metanol
ES8602789A1 (es) Procedimiento para preparar derivados de 14-hidroxiimino- eburnano racemicos y opticamente activos
ES8707505A2 (es) Mejoras en el objeto de la patente de invencion n.541.911 por procedimiento de obtencion de nuevos derivados de alfa-(alquilaminopropionil)-tiofeno sustituidos en el anillo tiofenico
JO1346B1 (en) The salts of the anti-malarial compounds Phenantrine Methanol
JPS5436252A (en) Novel propano-anthracene derivatives and their preparation